tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Tarsus Pharmaceuticals Inc

TARS
Add to Watchlist
90.800USD
+7.595+9.13%
Close 09-04 16:00（ET）
3.93BMarket Cap
LossP/E TTM

Tarsus Pharmaceuticals Inc

90.800
+7.595+9.13%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

TARS Financials

See Tarsus Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Tarsus Pharmaceuticals Inc Earnings Date

Latest Release
Aug 6, 2026
EPS / Forecast
-0.43/-0.20
Revenue / Forecast
173.91M/169.68M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
451.36M
146.71%
EPS(YoY)
-1.59
48.27%
Analyst Rating
STRONG BUY
2026/09/06
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
10.97%-0.43
74.60%-0.16
67.34%-0.20
51.59%-0.30
45.45%-0.48
36.92%-0.64
52.31%-0.60
52.27%-0.61
24.89%-0.88
-15.58%-1.01
-146.86%-1.26
---1.28
---1.17
---0.88
---0.51
---2.03
----
----
----
----
Revenue
69.41%173.91M
106.87%162.05M
128.39%151.67M
146.68%118.70M
151.54%102.66M
183.68%78.33M
407.86%66.41M
2471.78%48.12M
--40.81M
1004.56%27.61M
30.76%13.08M
--1.87M
-100.00%0.00
363.82%2.50M
2858.58%10.00M
-100.00%0.00
-30.61%15.28M
-98.39%539.00K
--338.00K
--1.24M
Net Profit
8.80%-18.55M
72.27%-6.97M
63.77%-8.37M
46.26%-12.59M
38.90%-20.34M
29.70%-25.12M
44.84%-23.11M
40.18%-23.42M
-5.94%-33.29M
-52.57%-35.73M
-208.13%-41.90M
-73.91%-39.15M
-447.17%-31.42M
-15.72%-23.42M
8.39%-13.60M
-43.41%-22.51M
-191.17%-5.74M
-296.75%-20.24M
-29.45%-14.84M
-54.83%-15.70M
Net Margin
46.16%-10.67%
86.59%-4.30%
84.14%-5.52%
78.22%-10.60%
75.71%-19.81%
75.22%-32.07%
89.14%-34.80%
97.67%-48.67%
---81.57%
86.19%-129.39%
-135.64%-320.45%
---2092.36%
----
---936.76%
---135.99%
---306.60%
----
----
----
----
Gross Margin
-0.95%93.03%
0.91%94.20%
0.23%92.80%
-0.28%93.00%
1.39%93.92%
-0.70%93.35%
2.07%92.58%
16.80%93.26%
--92.64%
-5.99%94.01%
-5.52%90.70%
--79.85%
----
--100.00%
--96.00%
--96.49%
----
----
----
----
Debt to assets ratio
-18.29%11.91%
-13.10%12.49%
-32.39%12.89%
-29.04%13.52%
-23.28%14.57%
67.74%14.38%
69.68%19.06%
72.12%19.06%
45.83%18.99%
-26.16%8.57%
31.69%11.23%
--11.07%
--13.02%
--11.61%
--8.53%
--8.19%
----
----
----
----
Income Statement
Revenue
69.41%173.91M
106.87%162.05M
128.39%151.67M
146.68%118.70M
151.54%102.66M
183.68%78.33M
407.86%66.41M
2471.78%48.12M
--40.81M
1004.56%27.61M
30.76%13.08M
--1.87M
-100.00%0.00
363.82%2.50M
2858.58%10.00M
-100.00%0.00
-30.61%15.28M
-98.39%539.00K
--338.00K
--1.24M
Operating profit
10.26%-19.91M
76.70%-6.12M
67.34%-7.98M
42.26%-14.53M
33.39%-22.18M
30.26%-26.28M
45.06%-24.42M
38.53%-25.16M
-1.47%-33.30M
-51.03%-37.68M
-195.13%-44.45M
-78.71%-40.94M
-528.27%-32.82M
-27.82%-24.95M
-4.24%-15.06M
-45.85%-22.91M
-171.74%-5.22M
-282.20%-19.52M
-25.89%-14.45M
-54.87%-15.71M
Net Profit
8.80%-18.55M
72.27%-6.97M
63.77%-8.37M
46.26%-12.59M
38.90%-20.34M
29.70%-25.12M
44.84%-23.11M
40.18%-23.42M
-5.94%-33.29M
-52.57%-35.73M
-208.13%-41.90M
-73.91%-39.15M
-447.17%-31.42M
-15.72%-23.42M
8.39%-13.60M
-43.41%-22.51M
-191.17%-5.74M
-296.75%-20.24M
-29.45%-14.84M
-54.83%-15.70M
Balance Sheet
Current assets
18.46%561.99M
11.74%537.23M
46.56%522.78M
40.49%501.70M
30.85%474.43M
41.10%480.77M
39.27%356.70M
37.74%357.12M
97.62%362.59M
63.30%340.72M
13.65%256.13M
10.77%259.28M
-26.69%183.48M
16.72%208.65M
28.09%225.38M
25.12%234.08M
24.58%250.28M
-6.63%178.75M
3.10%175.95M
110.04%187.09M
Total current liabilities
94.73%175.75M
66.27%143.51M
68.33%135.69M
77.70%117.05M
75.01%90.25M
102.94%86.31M
118.25%80.61M
183.32%65.87M
249.28%51.57M
220.84%42.53M
139.39%36.94M
62.89%23.25M
26.00%14.77M
5.11%13.26M
34.42%15.43M
37.70%14.27M
12.08%11.72M
24.63%12.61M
113.07%11.48M
68.70%10.37M
Total assets
23.46%611.14M
16.05%581.13M
49.12%562.16M
42.06%534.56M
31.35%494.99M
43.37%500.75M
42.00%376.99M
40.24%376.30M
99.47%376.84M
65.37%349.28M
16.51%265.49M
13.48%268.33M
-25.27%188.93M
16.38%211.21M
27.36%227.86M
24.19%236.47M
24.27%252.83M
-6.43%181.48M
4.03%178.91M
106.55%190.41M
Total liabilities
62.83%264.41M
46.68%232.18M
43.47%218.73M
43.70%199.48M
30.32%162.38M
113.71%158.29M
122.56%152.46M
153.93%138.82M
202.44%124.60M
95.89%74.07M
95.93%68.50M
61.56%54.67M
31.53%41.20M
17.11%37.81M
187.12%34.96M
200.25%33.84M
185.30%31.32M
201.12%32.29M
103.22%12.18M
64.41%11.27M
Total equity
4.25%346.73M
1.90%348.95M
52.95%343.43M
41.10%335.08M
31.86%332.61M
24.43%342.46M
13.98%224.53M
11.15%237.48M
70.75%252.25M
58.71%275.21M
2.12%196.99M
5.45%213.66M
-33.31%147.73M
16.22%173.40M
15.70%192.90M
13.11%202.63M
15.08%221.50M
-18.57%149.20M
0.45%166.73M
109.94%179.14M
Cash Flow Statement
Net operating income
308.33%61.22M
-19.37%-24.65M
187.14%19.33M
311.01%18.26M
-104.02%-29.39M
45.35%-20.65M
43.61%-22.18M
73.26%-8.65M
39.55%-14.40M
-72.00%-37.79M
-261.73%-39.34M
-73.89%-32.36M
-459.43%-23.83M
-43.73%-21.97M
10.29%-10.87M
-361.68%-18.61M
-120.72%-4.26M
-29.61%-15.29M
-21.05%-12.12M
208.22%7.11M
Net investment
173.26%37.88M
-67.60%-58.56M
182.71%49.27M
-251.63%-4.74M
-27.59%-51.70M
65.82%-34.94M
-433.75%-59.57M
-93.40%3.13M
-163.23%-40.52M
-1005.12%-102.22M
120.47%17.85M
182.92%47.37M
52634.43%64.09M
7114.91%11.29M
-31731.75%-87.22M
-47112.40%-57.13M
-662.50%-122.00K
8.00%-161.00K
-648.00%-274.00K
10.37%-121.00K
Net financing
69.16%3.30M
-99.12%1.20M
-21.01%2.31M
300.94%2.56M
-95.39%1.95M
25.55%136.56M
-85.19%2.93M
-99.39%639.00K
8197.84%42.32M
2069.78%108.77M
7384.85%19.76M
77227.21%104.89M
-99.32%510.00K
-73.79%5.01M
456.76%264.00K
-281.33%-136.00K
7473300.00%74.73M
100557.89%19.13M
-100.08%-74.00K
-99.81%75.00K

FAQs

What is the total revenue of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 451.36M, with a year-on-year change of 182.95M.

What are the current assets of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its current assets were 522.78M, with a year-on-year change of 46.56.

What are the total assets of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its total assets of Tarsus Pharmaceuticals Inc were 562.16M, with a year-on-year change of 49.12.

What are the total liabilities of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Tarsus Pharmaceuticals Inc were 218.73M, with a year-on-year change of 43.47.

What is the total equity of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its total equity of Tarsus Pharmaceuticals Inc was 343.43M, with a year-on-year change of 52.95.

What is the net operating income of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Tarsus Pharmaceuticals Inc was -70.97M, with a year-on-year change of 41.14.

What is the net investment of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its net investment of Tarsus Pharmaceuticals Inc was -42.12M, with a year-on-year change of 78.86.

What is the net financing of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its net financing of Tarsus Pharmaceuticals Inc was 143.39M, with a year-on-year change of -7.29.

What is the Earnings Per Share (EPS) of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -1.59, with a year-on-year change of 48.27.

What is the net income of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its net income was -66.42M, with a year-on-year change of 42.52.

What is the net margin of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was -14.72, with a year-on-year change of 76.70.

What is the gross margin of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 93.20, with a year-on-year change of 0.23.

What is the debt-to-asset ratio of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 12.89, with a year-on-year change of -32.39.

What is the Return on Equity (ROE) of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -23.39, with a year-on-year change of 57.34.

What is the Return on Assets (ROA) of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -14.14, with a year-on-year change of 60.68.

What is the operating profit of Tarsus Pharmaceuticals Inc?

According to Tarsus Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -70.97M, with a year-on-year change of 41.14.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy